Patent ID: 8329755

Claim:
A pharmaceutical composition for treating an HIV infection comprising a therapeutically effective quantity of a compound according to formula I admixed with at least one carrier, excipient or diluent wherein: X 1 is —O—; R 1 and R 2 are (i) each independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 sulfonyl, C 1-6 haloalkoxy, C 1-6 haloalkylthio, halogen, amino, C 1-6 alkylamino, C 1-6 dialkylamino, C 1-6 acylamino, nitro and cyano; or, (ii) together R 1 and R 2 are —O—CH═CH— or —O—CH 2 CH 2 —; R 3 and R 4 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy C 1-6 alkylthio, C 1-6 haloalkylthio, halogen, amino, nitro and cyano; R 5 is phenyl optionally substituted with one to three substituents independently selected from the group consisting of halogen and cyano; Ar is phenyl substituted S(O) n NR 8 R 9 and optionally further substituted by with 1 or 2 substituents independently selected in each incidence is from the group consisting of C 1-6 alkyl—and halogen—with the proviso that at least one carbon adjacent to the carbon substituted by the nitrogen is substituted by hydrogen; R 8 and R 9 (i) taken independently, one of R 8 and R 9 is hydrogen or C 1-6 alkyl and the other of R 8 and R 9 is selected from the group consisting of hydrogen, —C(═O)R 14 , —C(═O)CHR 12 NH 2 , —(CH 2 ) 2 N[(CH 2 ) 2 ] 2 O, COCO 2 Me, C 3-8 cycloalkyl said cycloalkyl optionally substituted with one or two hydroxyl substituents, pyranyl, C 1-6 alkyl and aryl said alkyl and said aryl groups optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, C 1-6 alkoxy, thiol, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 sulfonyl, and halogen; or, (ii) R 8 and R 9 taken together are (CH 2 ) 2 —X 5 —(CH 2 ) 2 or —(CH 2 ) o — optionally substituted with one or two substituents selected from the group consisting of halogen, hydroxyl and NR 11a R 11b ; R 8a and R 9a (i) taken independently are selected from the group consisting of hydrogen, C 1-6 alkyl, C(═O)CO 2 R 11 and SO 2 R 10 , or (ii) taken together are (CH 2 ) r SO 2 , (CH 2 ) 2 S(O) p (CH 2 ) 2 ; R 10 is C 1-6 alkyl; R 11 is hydrogen or C 1-6 alkyl; R 11a , R 11b and R 11c are independently R 11 ; R 12 is the side chain of a) naturally occurring α-amino acid; R 14 is C 1-6 alkyl, —(CH 2 ) s NHR 11a R 11b , —(CH 2 ) s OR 11 , —CH 2 CH(OH)CH 3 , —CH 2 N[(CH 2 ) 2 ] 2 O, —(CH 2 ) 2 CO 2 R 11 , optionally substituted phenyl or pyridinyl; X 5 is —O—, —S(O) n — or NR 11 ; n is an integer from 0 to 2; o is an integer from 4 to 6; r is an integer from 3 to 4 s is an integer from 1 to 2; or a pharmaceutically acceptable salt thereof.